Opinion|Videos|August 5, 2024
Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities
Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.
Advertisement
Episodes in this series
- Briefly comment on recent real world data regarding switching and sequencing to next line of therapy in patients with CLL. (
Pinilla-Ibarz, et al. EHA 2024. Abstract P697 )
- How do you interpret these data and how may they influence your overall treatment approach?
Advertisement
Related to this article
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
The NMPA has approved pirtobrutinib in treatment-naive and previously treated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
OncLive Weekly News Quiz (10/9/2026): Did You Miss Crucial Colon Cancer, Myeloma, Breast Cancer, and Lung Cancer Updates?
4
Next-Generation NAMPT Inhibitors Aim to Revive a Stalled Target in AML and MDS
5